Please enable JavaScript to continue using this application.

Compare $DSGN vs $FDMT | Chartloom

Compare

$DSGN vs $FDMT

Design Therapeutics Inc · 4D Molecular Therapeutics Inc

DSGN

Design Therapeutics Inc

FDMT

4D Molecular Therapeutics Inc

Compare $DSGN vs $FDMT

Comparing Design Therapeutics Inc and 4D Molecular Therapeutics Inc

DSGNDesign Therapeutics Inc

FDMT4D Molecular Therapeutics Inc

DSGNDesign Therapeutics Inc

Market cap

$728M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

28.0%

52W performance

67.9%

FCF yield

-7.6%

FDMT4D Molecular Therapeutics Inc

Market cap

$697M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

50.39x

Rev growth (TTM)

278712.1%

YTD performance

82.1%

52W performance

38.0%

FCF yield

-22.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

DSGN

FDMT

Detailed metrics comparison

DSGN

Design Therapeutics Inc

FDMT

4D Molecular Therapeutics Inc

Market Cap

DSGN$728M

FDMT$697M

Enterprise Value

DSGN$715M

FDMT$646M

Price

DSGN$11.65

FDMT$13.33

P/E Ratio

DSGNN/A

FDMTN/A

P/S Ratio

DSGN0.00x

FDMT7.57x

EV/Sales

DSGN0.00x

FDMT7.02x

EV/EBITDA

DSGN0.00x

FDMT0.00x

P/B Ratio

DSGN3.83x

FDMT1.85x

P/FCF Ratio

DSGNN/A

FDMTN/A

EV/FCF

DSGN-12.96x

FDMT-4.13x

PEG Ratio

DSGNN/A

FDMTN/A

Forward P/E (NTM)

DSGNN/A

FDMTN/A

Forward P/S (NTM)

DSGNN/A

FDMT50.39x

Revenue (TTM)

DSGN$0

FDMT$92M

Revenue Growth (YoY)

DSGNN/A

FDMT278712.1%

Forward Rev Growth

DSGN1360.4%

FDMT40.6%

Gross Margin (TTM)

DSGN0.0%

FDMT0.0%

Operating Margin (TTM)

DSGN0.0%

FDMT0.0%

EBITDA Margin (TTM)

DSGN0.0%

FDMT-208.8%

Net Margin (TTM)

DSGN0.0%

FDMT-194.7%

FCF Margin (TTM)

DSGNN/A

FDMT-169.9%

Net Income (TTM)

DSGN$-71M

FDMT$-179M

FCF (TTM)

DSGN$-55M

FDMT$-156M

EPS (TTM)

DSGN-$1.13

FDMT-$2.55

ROE (TTM)

DSGN-3403.0%

FDMT-4133.0%

ROA (TTM)

DSGN-3205.0%

FDMT-3590.0%

ROIC (TTM)

DSGN-3403.0%

FDMT-4087.0%

Cash

DSGN$13M

FDMT$70M

Debt

DSGN$0

FDMT$20M

Net Cash/Debt

DSGN$13M

FDMT$51M

Current Ratio (TTM)

DSGN18.86x

FDMT8.03x

Quick Ratio (TTM)

DSGN18.61x

FDMT7.68x

Debt/Equity (TTM)

DSGN0.00x

FDMT0.05x

Debt/Assets (TTM)

DSGN0.0%

FDMT0.0%

Interest Coverage (TTM)

DSGNN/A

FDMTN/A

Net Debt/EBITDA (TTM)

DSGN0.00x

FDMT0.00x

Beta

DSGN1.72

FDMT2.90

52W Performance

DSGN67.9%

FDMT38.0%

YTD Performance

DSGN28.0%

FDMT82.1%

% from 52W High

DSGN-32.5%

FDMT-21.3%

% from 52W Low

DSGN120.6%

FDMT91.5%

Asset Turnover (TTM)

DSGN0.00x

FDMT0.18x

FCF Yield (TTM)

DSGN-7.6%

FDMT-22.4%

Earnings Yield (TTM)

DSGN-9.7%

FDMT-25.7%

Dividend Yield (TTM)

DSGNN/A

FDMTN/A

Rule of 40

DSGN0.0

FDMT278,542.3

EV/GP/RG

DSGNN/A

FDMTN/A

Ticker research

View DSGN research View FDMT research

Metric	DSGN Design Therapeutics Inc	FDMT 4D Molecular Therapeutics Inc
Market & Valuation
Market Cap	$728M	$697M
Enterprise Value	$715M	$646M
Price	$11.65	$13.33
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	7.57x
EV/Sales	0.00x	7.02x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.83x	1.85x
P/FCF Ratio	N/A	N/A
EV/FCF	-12.96x	-4.13x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	50.39x
Revenue & Growth
Revenue (TTM)	$0	$92M
Revenue Growth (YoY)	N/A	278712.1%
Forward Rev Growth	1360.4%	40.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-208.8%
Net Margin (TTM)	0.0%	-194.7%
FCF Margin (TTM)	N/A	-169.9%
Net Income (TTM)	$-71M	$-179M
FCF (TTM)	$-55M	$-156M
EPS (TTM)	-$1.13	-$2.55
ROE (TTM)	-3403.0%	-4133.0%
ROA (TTM)	-3205.0%	-3590.0%
ROIC (TTM)	-3403.0%	-4087.0%
Financial Health
Cash	$13M	$70M
Debt	$0	$20M
Net Cash/Debt	$13M	$51M
Current Ratio (TTM)	18.86x	8.03x
Quick Ratio (TTM)	18.61x	7.68x
Debt/Equity (TTM)	0.00x	0.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.72	2.90
52W Performance	67.9%	38.0%
YTD Performance	28.0%	82.1%
% from 52W High	-32.5%	-21.3%
% from 52W Low	120.6%	91.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.18x
FCF Yield (TTM)	-7.6%	-22.4%
Earnings Yield (TTM)	-9.7%	-25.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	278,542.3
EV/GP/RG	N/A	N/A
Ticker research	View DSGN research	View FDMT research

Valuation

P/S Ratio

DSGN

0.00x

FDMT

7.57x

EV/FCF

DSGN

-12.96x

FDMT

-4.13x

Growth & revenue

Revenue Growth TTM

FDMT

278712.1%

Forward Revenue Growth

DSGN

1360.4%

FDMT

40.6%

Profitability & performance

Gross Margin

DSGN

0.0%

FDMT

0.0%

ROE

DSGN

-3403.0%

FDMT

-4133.0%

FCF Yield %

DSGN

-7.6%

FDMT

-22.4%

52-Week Performance

DSGN

67.9%

FDMT

38.0%

Detailed metrics comparison

DSGN

Design Therapeutics Inc

FDMT

4D Molecular Therapeutics Inc

Market Cap

DSGN$728M

FDMT$697M

Enterprise Value

DSGN$715M

FDMT$646M

Price

DSGN$11.65

FDMT$13.33

P/E Ratio

DSGNN/A

FDMTN/A

P/S Ratio

DSGN0.00x

FDMT7.57x

EV/Sales

DSGN0.00x

FDMT7.02x

EV/EBITDA

DSGN0.00x

FDMT0.00x

P/B Ratio

DSGN3.83x

FDMT1.85x

P/FCF Ratio

DSGNN/A

FDMTN/A

EV/FCF

DSGN-12.96x

FDMT-4.13x

PEG Ratio

DSGNN/A

FDMTN/A

Forward P/E (NTM)

DSGNN/A

FDMTN/A

Forward P/S (NTM)

DSGNN/A

FDMT50.39x

Revenue (TTM)

DSGN$0

FDMT$92M

Revenue Growth (YoY)

DSGNN/A

FDMT278712.1%

Forward Rev Growth

DSGN1360.4%

FDMT40.6%

Gross Margin (TTM)

DSGN0.0%

FDMT0.0%

Operating Margin (TTM)

DSGN0.0%

FDMT0.0%

EBITDA Margin (TTM)

DSGN0.0%

FDMT-208.8%

Net Margin (TTM)

DSGN0.0%

FDMT-194.7%

FCF Margin (TTM)

DSGNN/A

FDMT-169.9%

Net Income (TTM)

DSGN$-71M

FDMT$-179M

FCF (TTM)

DSGN$-55M

FDMT$-156M

EPS (TTM)

DSGN-$1.13

FDMT-$2.55

ROE (TTM)

DSGN-3403.0%

FDMT-4133.0%

ROA (TTM)

DSGN-3205.0%

FDMT-3590.0%

ROIC (TTM)

DSGN-3403.0%

FDMT-4087.0%

Cash

DSGN$13M

FDMT$70M

Debt

DSGN$0

FDMT$20M

Net Cash/Debt

DSGN$13M

FDMT$51M

Current Ratio (TTM)

DSGN18.86x

FDMT8.03x

Quick Ratio (TTM)

DSGN18.61x

FDMT7.68x

Debt/Equity (TTM)

DSGN0.00x

FDMT0.05x

Debt/Assets (TTM)

DSGN0.0%

FDMT0.0%

Interest Coverage (TTM)

DSGNN/A

FDMTN/A

Net Debt/EBITDA (TTM)

DSGN0.00x

FDMT0.00x

Beta

DSGN1.72

FDMT2.90

52W Performance

DSGN67.9%

FDMT38.0%

YTD Performance

DSGN28.0%

FDMT82.1%

% from 52W High

DSGN-32.5%

FDMT-21.3%

% from 52W Low

DSGN120.6%

FDMT91.5%

Asset Turnover (TTM)

DSGN0.00x

FDMT0.18x

FCF Yield (TTM)

DSGN-7.6%

FDMT-22.4%

Earnings Yield (TTM)

DSGN-9.7%

FDMT-25.7%

Dividend Yield (TTM)

DSGNN/A

FDMTN/A

Rule of 40

DSGN0.0

FDMT278,542.3

EV/GP/RG

DSGNN/A

FDMTN/A

Ticker research

View DSGN research View FDMT research

Metric	DSGN Design Therapeutics Inc	FDMT 4D Molecular Therapeutics Inc
Market & Valuation
Market Cap	$728M	$697M
Enterprise Value	$715M	$646M
Price	$11.65	$13.33
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	7.57x
EV/Sales	0.00x	7.02x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.83x	1.85x
P/FCF Ratio	N/A	N/A
EV/FCF	-12.96x	-4.13x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	50.39x
Revenue & Growth
Revenue (TTM)	$0	$92M
Revenue Growth (YoY)	N/A	278712.1%
Forward Rev Growth	1360.4%	40.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-208.8%
Net Margin (TTM)	0.0%	-194.7%
FCF Margin (TTM)	N/A	-169.9%
Net Income (TTM)	$-71M	$-179M
FCF (TTM)	$-55M	$-156M
EPS (TTM)	-$1.13	-$2.55
ROE (TTM)	-3403.0%	-4133.0%
ROA (TTM)	-3205.0%	-3590.0%
ROIC (TTM)	-3403.0%	-4087.0%
Financial Health
Cash	$13M	$70M
Debt	$0	$20M
Net Cash/Debt	$13M	$51M
Current Ratio (TTM)	18.86x	8.03x
Quick Ratio (TTM)	18.61x	7.68x
Debt/Equity (TTM)	0.00x	0.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.72	2.90
52W Performance	67.9%	38.0%
YTD Performance	28.0%	82.1%
% from 52W High	-32.5%	-21.3%
% from 52W Low	120.6%	91.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.18x
FCF Yield (TTM)	-7.6%	-22.4%
Earnings Yield (TTM)	-9.7%	-25.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	278,542.3
EV/GP/RG	N/A	N/A
Ticker research	View DSGN research	View FDMT research